Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lecia Vandam Sequist, M.D.

Title
Institution
Department
Address
Phone

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. R61CA287026 (HAAS, WILHELM) Feb 12, 2024 - Jan 31, 2027
    NIH
    A Real-Time AI-Driven High-Throughput Proteomics Data Acquisition Method for Clinical Applications
    Role: Co-Principal Investigator
  2. P50CA265826 (BARBIE, DAVID A) Aug 1, 2022 - Jul 31, 2027
    NIH
    Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
    Role: Co-Principal Investigator
  3. R21CA156000 (SEQUIST, LECIA V.) May 1, 2011 - Apr 30, 2013
    NIH
    Repeat Biopsies in Lung Cancer to Define Targeted Resistance Mechanisms
    Role: Principal Investigator
  4. R01CA137008 (HATA, AARON N) Mar 1, 2009 - May 31, 2027
    NIH
    Non-genomic resistance mechanisms in EGFR-mutant lung cancer
    Role: Co-Principal Investigator
  5. T32CA071345 (HABER, DANIEL A.) Aug 1, 1997 - Jun 30, 2028
    NIH
    Training Program in Cancer Biology and Therapeutics
    Role: Co-Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Displaying 25 of 320 total Publications Show all
  1. Mishra A, Huang SB, Dubash T, Burr R, Edd JF, Wittner BS, Cunneely QE, Putaturo VR, Deshpande A, Antmen E, Gopinathan KA, Otani K, Miyazawa Y, Kwak JE, Guay SY, Kelly J, Walsh J, Nieman LT, Galler I, Chan P, Lawrence MS, Sullivan RJ, Bardia A, Micalizzi DS, Sequist LV, Lee RJ, Franses JW, Ting DT, Brunker PAR, Maheswaran S, Miyamoto DT, Haber DA, Toner M. Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. Nat Commun. 2025 Jan 02; 16(1):32. PMID: 39746954; PMCID: PMC11696112.
    Citations:
    Fields: BioBiologySciScienceTranslation:HumansCells
  2. Keane FK, Yeap BY, Khandekar MJ, Lin JJ, Dagogo-Jack I, Sequist LV, Piotrowska Z, Willers H. Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors. Int J Radiat Oncol Biol Phys. 2024 Nov 20. PMID: 39577475.
    Citations:
    Fields: NeoNeoplasmsRadRadiologyRadRadiotherapy
  3. Dagogo-Jack I, Cooper AJ, Johnson BE, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Digumarthy SR, Mino-Kenudson M, Muzikansky A, Shaw AT. Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study. Lung Cancer. 2025 Jan; 199:108003. PMID: 39615410.
    Citations:
    Fields: NeoNeoplasms
  4. Mazzone PJ, Bach PB, Carey J, Schonewolf CA, Bognar K, Ahluwalia MS, Cruz-Correa M, Gierada D, Kotagiri S, Lloyd K, Maldonado F, Ortendahl JD, Sequist LV, Silvestri GA, Tanner N, Thompson JC, Vachani A, Wong KK, Zaidi AH, Catallini J, Gershman A, Lumbard K, Millberg LK, Nawrocki J, Portwood C, Rangnekar A, Sheridan CC, Trivedi N, Wu T, Zong Y, Cotton L, Ryan A, Cisar C, Leal A, Dracopoli N, Scharpf RB, Velculescu VE, Pike LRG. Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection. Cancer Discov. 2024 Nov 01; 14(11):2224-2242. PMID: 38829053; PMCID: PMC11528203.
    Citations: 3
    Fields: NeoNeoplasms
  5. Simon J, Mikhael P, Graur A, Chang AEB, Skates SJ, Osarogiagbon RU, Sequist LV, Fintelmann FJ. Significance of Image Reconstruction Parameters for Future Lung Cancer Risk Prediction Using Low-Dose Chest Computed Tomography and the Open-Access Sybil Algorithm. Invest Radiol. 2024 Oct 23. PMID: 39437009.
    Citations:
    Fields: RadRadiology
  6. Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, Barth JL, Dubash T, Chirn B, Parida L, Sequist LV, Lennerz JK, Mino-Kenudson M, Maheswaran S, Naxerova K, Getz G, Haber DA. Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors. Nat Cancer. 2024 Nov; 5(11):1681-1696. PMID: 39406916; PMCID: PMC11584400.
    Citations:
    Fields: NeoNeoplasms
  7. Chang AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, Muzikansky A, Rotow J, Jänne PA, Mino-Kenudson M, Swanson S, Wright CD, Kozono D, Marcoux P, Piotrowska Z, Sequist LV, Willers H. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist. 2024 Jul 05; 29(7):609-618. PMID: 38761385; PMCID: PMC11224994.
    Citations: 6
    Fields: NeoNeoplasmsTranslation:HumansCTClinical Trials
  8. Felip E, Metro G, Soo RA, Wolf J, Solomon BJ, Tan DS, Ardizzoni A, Lee DH, Sequist LV, Barlesi F, Ponce-Aix S, Abreu DR, Campelo MRG, Sprauten M, Djentuh LO, Smith N, Jary A, Belli R, Glaser S, Zou M, Cui X, Giovannini M, Yang JC. Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer. Eur J Cancer. 2024 Sep; 208:114182. PMID: 38986421.
    Citations:
    Fields: NeoNeoplasmsTranslation:HumansCTClinical Trials
  9. Chang AEB, Potter AL, Yang CJ, Sequist LV. Early Detection and Interception of Lung Cancer. Hematol Oncol Clin North Am. 2024 08; 38(4):755-770. PMID: 38724286.
    Citations:
    Fields: HemHematologyNeoNeoplasmsTranslation:HumansPHPublic Health
  10. Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO Precis Oncol. 2024 Apr; 8:e2300454. PMID: 38591867; PMCID: PMC10896470.
    Citations: 1
    Fields: NeoNeoplasmsTranslation:CTClinical Trials
  11. Potter AL, Xu NN, Senthil P, Srinivasan D, Lee H, Gazelle GS, Chelala L, Zheng W, Fintelmann FJ, Sequist LV, Donington J, Palmer JR, Yang CJ. Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility. J Clin Oncol. 2024 Jun 10; 42(17):2026-2037. PMID: 38537159; PMCID: PMC11191064.
    Citations: 1
    Fields: NeoNeoplasmsTranslation:Humans
  12. Mishra A, Huang SB, Dubash T, Burr R, Edd JF, Wittner BS, Cunneely QE, Putaturo VR, Deshpande A, Antmen E, Gopinathan KA, Otani K, Miyazawa Y, Kwak JE, Guay SY, Kelly J, Walsh J, Nieman L, Galler I, Chan P, Lawrence MS, Sullivan RJ, Bardia A, Micalizzi DS, Sequist LV, Lee RJ, Franses JW, Ting DT, Brunker PAR, Maheswaran S, Miyamoto DT, Haber DA, Toner M. Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. bioRxiv. 2024 Mar 14. PMID: 38559183; PMCID: PMC10980012.
    Citations:
  13. Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 Apr 10; 42(11):e1-e22. PMID: 38417091.
    Citations: 6
    Fields: NeoNeoplasmsTranslation:Humans
  14. Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, Masters G, Schenk EL, Schneider BJ, Sequist L, Singh N, Bazhenova L, Blanchard E, Freeman-Daily J, Furuya N, Halmos B, Azar IH, Kuruvilla S, Mullane M, Naidoo J, Reuss JE, Spigel DR, Owen DH, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3. J Clin Oncol. 2024 Apr 10; 42(11):e23-e43. PMID: 38417098.
    Citations: 5
    Fields: NeoNeoplasmsTranslation:Humans
  15. Micalizzi DS, Sequist LV, Haber DA. Deploying blood-based cancer screening. Science. 2024 Jan 26; 383(6681):368-370. PMID: 38271495.
    Citations: 1
    Fields: SciScienceTranslation:HumansPHPublic Health
  16. Sequist LV, Warner ET, Yang CJ. Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs. JAMA Oncol. 2023 Dec 01; 9(12):1649-1650. PMID: 37883100.
    Citations:
    Fields: NeoNeoplasmsTranslation:Humans
  17. Sequist LV, Olazagasti C. Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a Sprint. Radiology. 2023 11; 309(2):e232850. PMID: 37934096.
    Citations:
    Fields: RadRadiologyTranslation:Humans
  18. Simon J, Mikhael P, Tahir I, Graur A, Ringer S, Fata A, Jeffrey YC, Shepard JA, Jacobson F, Barzilay R, Sequist LV, Pace LE, Fintelmann FJ. Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography. Sci Rep. 2023 10 30; 13(1):18611. PMID: 37903855; PMCID: PMC10616081.
    Citations:
    Fields: SciScienceTranslation:Humans
  19. Florez N, Kiel L, Riano I, Patel S, DeCarli K, Dhawan N, Franco I, Odai-Afotey A, Meza K, Swami N, Patel J, Sequist LV. Lung Cancer in Women: The Past, Present, and Future. Clin Lung Cancer. 2024 01; 25(1):1-8. PMID: 37940410.
    Citations: 3
    Fields: NeoNeoplasmsPulPulmonary MedicineTranslation:Humans
  20. Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, Barth JL, Dubash T, Chirn B, Parida L, Sequist LV, Lennerz JK, Mino-Kenudson M, Maheswaran S, Naxerova K, Getz G, Haber DA. Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer. medRxiv. 2023 Sep 29. PMID: 37808694; PMCID: PMC10557804.
    Citations:
  21. Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF, Siddiqui FM, Phan N, Jalili P, Timonina D, Bilton S, Gomez-Caraballo M, Archibald HL, Nangia V, Dionne K, Riley A, Lawlor M, Banwait MK, Cobb RG, Zou L, Dyson NJ, Ott CJ, Benes C, Getz G, Chan CS, Shaw AT, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Yeap BY, Engelman JA, Lee JJ, Maruvka YE, Buisson R, Lawrence MS, Hata AN. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature. 2023 Aug; 620(7973):393-401. PMID: 37407818; PMCID: PMC10804446.
    Citations: 30
    Fields: SciScienceTranslation:Humans
  22. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol. 2023 06 01; 41(16):2869-2876. PMID: 37235976.
    Citations: 11
    Fields: NeoNeoplasmsTranslation:CTClinical Trials
  23. Dagogo-Jack I, Kiedrowski LA, Heist RS, Lin JJ, Meador CB, Krueger EA, Do A, Peterson J, Sequist LV, Gainor JF, Lennerz JK, Digumarthy SR. Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis. JTO Clin Res Rep. 2023 Aug; 4(8):100534. PMID: 37533439; PMCID: PMC10391652.
    Citations: 10
  24. Dagogo-Jack I, Valiev I, Kotlov N, Belozerova A, Lopareva A, Butusova A, Samarina N, Boyko A, Xiang Z, Johnson M, Degryse S, Keane FK, Sequist LV, Lanuti M, Fowler N, Mino-Kenudson M, Bagaev A. B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma. JTO Clin Res Rep. 2023 Jul; 4(7):100527. PMID: 37521368; PMCID: PMC10372172.
    Citations: 1
  25. Adams SJ, Mikhael P, Wohlwend J, Barzilay R, Sequist LV, Fintelmann FJ. Artificial Intelligence and Machine Learning in Lung Cancer Screening. Thorac Surg Clin. 2023 Nov; 33(4):401-409. PMID: 37806742.
    Citations: 3
    Fields: GenGeneral SurgeryPulPulmonary MedicineTranslation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contact@catalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resources@hms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappt@hms.harvard.edu.
Sequist's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (532)
Explore
_
Co-Authors (197)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
© 2025 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.